
GLP medications have become extremely popular because they address two of the most common chronic health problems at the same time: obesity and type 2 diabetes. They also produce substantially more weight loss than older medications, and their benefits appear to extend beyond blood sugar control. Most people are referring to GLP-1 receptor agonists or newer drugs that act on GLP-1 pathways.
GLP-1 stands for Glucagon-like peptide-1, a hormone naturally released by the intestine after eating. It helps:
- Increase insulin release when blood sugar rises
- Reduce glucagon (a hormone that raises blood sugar)
- Slow stomach emptying
- Increase feelings of fullness
- Reduce hunger and food cravings
The result is that many people eat less without constantly feeling deprived.
Why are they so popular right now?
1. They work better than previous weight-loss drugs
Older weight-loss medications often produced modest results.
Newer GLP-based drugs can produce average weight loss in the range of:
- About 10–15% of body weight with some GLP-1 medications
- Around 15–20% or more with newer dual-action drugs
For many patients, these outcomes begin approaching the effectiveness of some bariatric procedures.
2. Obesity is increasingly viewed as a chronic disease
Medical understanding has shifted away from viewing obesity solely as a matter of willpower. Researchers now recognize the role of hormones, genetics, metabolism, and brain reward pathways.
GLP medications target some of those biological drivers directly.
3. Celebrity and social media attention
High-profile use by celebrities and public discussion on platforms like TikTok, Instagram, and YouTube dramatically increased public awareness. Demand expanded far beyond people with diabetes.
4. Additional health benefits
Research suggests some GLP-based medications may reduce risks related to:
- Heart disease
- Kidney disease
- Sleep apnea
- Progression of type 2 diabetes
These potential benefits have increased enthusiasm among physicians and patients.
Major types of GLP medications
First-generation GLP-1 receptor agonists
These were among the earlier medications in the class.
Exenatide
- One of the earliest GLP-1 drugs
- Available in twice-daily and weekly forms
- Less commonly used today
Liraglutide
- Daily injection
- Approved for diabetes and weight management
- Produces meaningful but generally less weight loss than newer agents
Modern GLP-1 receptor agonists
Semaglutide
This is one of the most recognized GLP medications.
Brands include:
- Ozempic (diabetes)
- Wegovy (obesity)
- Rybelsus (oral tablet)
Key features:
- Usually taken once weekly (except oral form)
- Strong appetite suppression
- Significant weight loss
- Widely prescribed
Dual-action medications (GLP-1 + GIP)
These represent the newer generation.
Tirzepatide
Brands include:
- Mounjaro
- Zepbound
Tirzepatide activates:
- GLP-1 receptors
- GIP (glucose-dependent insulinotropic polypeptide) receptors
Many studies have found it produces greater average weight loss than semaglutide.
Triple-agonist drugs and future therapies
Researchers are developing drugs that act on:
- GLP-1
- GIP
- Glucagon receptors
One example is:
Retatrutide
Early trial results have generated considerable excitement because of the large weight-loss effects observed, though it is not yet broadly available in many markets.
Common side effects
The most frequent side effects are gastrointestinal:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Bloating
- Heartburn
These often improve as the body adjusts.
More serious but less common concerns can include:
- Gallbladder problems
- Pancreatitis
- Significant muscle loss if nutrition and resistance training are neglected
Limitations and controversies
Despite their popularity, GLP medications are not a perfect solution.
Challenges include:
- High cost
- Insurance coverage restrictions
- Drug shortages in some regions
- Weight regain after stopping treatment
- Need for long-term use for many patients
Researchers increasingly view these medications similarly to blood pressure or cholesterol treatments: many people may need ongoing therapy to maintain benefits.
Bottom line
GLP medications are popular because they target the biology of hunger and metabolism in a way that previous weight-loss treatments generally did not. The major categories are:
- Early GLP-1 drugs (e.g., Exenatide, Liraglutide)
- Modern GLP-1 drugs (e.g., Semaglutide)
- Dual GIP/GLP-1 drugs (e.g., Tirzepatide)
- Emerging triple-agonist therapies (e.g., Retatrutide)
The newer dual- and triple-action drugs are a major reason the field is receiving so much attention, as they are producing levels of weight loss that were difficult to achieve with medication just a few years ago.